/
Developing Predictive Models to Facilitate Interpretation of Toxicology Study Results

Developing Predictive Models to Facilitate Interpretation of Toxicology Study Results

Project Scope 

A computational pipeline to build models to predict target organs of toxicity from SEND datasets has been developed and published on GitHub under PHUSE. Project team members will evaluate the feasibility and performance of this pipeline when run on data from within their organisations. The pipeline will be updated to improve compatibility with different database systems, and efforts will be made to improve its performance across disparate data sources. Additional study interpretations – e.g. adversity of findings, NOAEL determination, clinical translatability, structure activity relationship – will be explored for development of predictive models. Successful modeling approaches will be published in peer-reviewed scientific journal articles.

Problem Statement 

Expert toxicologists spend hours interpreting the results of multiple studies to support the safety of new drug products. SEND data has enabled the construction of large databases of toxicology study results for building predictive models. These models can be trained using expert interpretations of old study data to make predictions that will streamline the interpretation of future studies.

Problem Impact 

Many hours are spent by both industry toxicologists and regulatory authority reviewers attempting to properly integrate and interpret the results of toxicology studies conducted to support drug safety. SEND data can be used to train models to use prior interpretations to predict likely interpretations of current studies. This approach will decrease time spent reviewing study results and increase study interpretation across toxicologists because the models will be trained on their interpretive conclusions. The models may also provide valuable insight into which toxicology study endpoints are most relevant for prediction of specific interpretations, e.g. hepatotoxicity, nephrotoxicity.

Project LeadsEmail 
Kevin Snyder, FDA

Kevin.Snyder@fda.hhs.gov

Lennart Anger, Genentech

Anger.lennart@gene.com
Alex Pearce, PHUSE Project AssistantAlexandra@phuse.global

CURRENT STATUS Q4 2024

  • Presentations at upcoming meetings of predictive modelling projects currently being pursued by members.

Objectives & DeliverablesTimelines
Evaluate the feasibility and performance of target organ prediction models developed by the FDA on data from other project members’ organisationsQ4 2024
Identify and prioritise a list of modeling endpoints – i.e. study interpretations – which would be most useful for additional predictive modeling approaches. Q4 2024
Iteratively improve upon the FDA modeling approach and develop, implement and test additional modeling approachesQ3 2025
Draft a manuscript describing successful modeling approachesQ3 2025

Related pages